# Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support

> **NCT03415594** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlyPharma Therapeutics** · enrollment: 8 (actual)

## Conditions studied

- Short Bowel Syndrome

## Interventions

- **DRUG:** FE203799 GLP-2 analogue
- **DRUG:** FE203799 Placebo GLP-2 analogue
- **DRUG:** FE203799 GLP-2 analogue

## Key facts

- **NCT ID:** NCT03415594
- **Lead sponsor:** GlyPharma Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-08
- **Primary completion:** 2019-11-21
- **Final completion:** 2019-11-21
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2024-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03415594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03415594, "Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03415594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*